ClinicalTrials.gg

Program

AZD0543

A development code.

Its studies are mostly in Paramyxoviridae Infections, led by AstraZeneca.

Furthest: phase 1, since Aug 28, 20261 company-led study, 1 open or runningNext primary completion: Mar 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since Aug 28, 2026Aug 28, 2026Mar 24, 2027phase 1 · NCT07824622
  • Named in AstraZeneca’s own pipeline as AZD0543, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2026First study: phase 1 study in Human Metapneumovirus InfectionFirst studyNCT07824622 · 144 planned · United States

Ahead

  1. Mar 24, 2027Primary completion: phase 1 study in Human Metapneumovirus InfectionNCT07824622

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07824622Human Metapneumovirus Infection · United States1RecruitingMar 24, 2027144

How it is read

Names in the registry

  • “AZD0543”, 1 entry

Codes read as this program: AZD0543.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.